NCT07067229 Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease
| NCT ID | NCT07067229 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chulalongkorn University |
| Condition | ALS (Amyotrophic Lateral Sclerosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-08-01 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Motor neuron disease (MND) is a progressive neurological disorder involving degeneration of motor neurons, leading to muscle weakness, speech and swallowing difficulties, and respiratory failure. This study aims to develop a novel treatment approach combining personalized repetitive transcranial magnetic stimulation (rTMS) with mixed reality (MR) exercise-based games (exergames) to slow disease progression and improve quality of life. In this randomised controlled trial study will compare three groups: (1) rTMS with MR exercise (personalized intervention), (2) rTMS with MR exercise (standard intervention), and (3) sham rTMS with MR exercise. Outcomes will be assessed at baseline, 3 months, and 6 months post intervention. The long-term goal is to implement this approach in clinical settings to enhance care for people with MND.
Eligibility Criteria
Inclusion Criteria: * Participants aged between 18 and 80 years * Diagnosed with any type of motor neuron disease (MND) * Have mild to moderate severity, as assessed by the Sinaki-Mulder scale, with a severity level between 1 and 3 Exclusion Criteria: * History of other neurological disorders, such as stroke * Use of ventilatory support * Severe dementia
Contact & Investigator
Jakkrit Amornvit, MD
PRINCIPAL INVESTIGATOR
Chulalongkorn University
Frequently Asked Questions
Who can join the NCT07067229 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying ALS (Amyotrophic Lateral Sclerosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07067229 currently recruiting?
Yes, NCT07067229 is actively recruiting participants. Contact the research team at jakkrit.a@chula.ac.th for enrollment information.
Where is the NCT07067229 trial being conducted?
This trial is being conducted at Bangkok, Thailand.
Who is sponsoring the NCT07067229 clinical trial?
NCT07067229 is sponsored by Chulalongkorn University. The principal investigator is Jakkrit Amornvit, MD at Chulalongkorn University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.